Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Core Insights - Cidara Therapeutics will report its Q1 2025 financial results and operational highlights on May 8, 2025, after U.S. market close [1] - A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies, including its lead candidate CD388, aimed at universal prevention of influenza [3] - CD388 received Fast Track Designation from the FDA in June 2023 and completed Phase 2b enrollment in December 2024 [3] - The company has also developed additional DFCs for oncology, including CBO421, which targets CD73 in solid tumors and received IND clearance in July 2024 [3]